Compare Stocks: SCNX, COCP, OPTH, and DARE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COCP Cocrystal Pharma	$1.02 -1.0%	$1.13	$0.76 ▼ $2.03	$19.84M	1.48	47,192 shs	22,775 shs
DARE Dare Bioscience	$0.72 -2.1%	$0.82	$0.69 ▼ $3.78	$14.56M	1.01	215,204 shs	77,209 shs
OPTH Optimi Health	$3.38 +6.0%	$4.59	$3.04 ▼ $6.40	$18.27M	N/A	35,560 shs	19,947 shs
SCNX Scienture	$3.36 -0.6%	$7.94	$3.21 ▼ $65.00	$5.55M	3.34	435,101 shs	24,146 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COCP Cocrystal Pharma	-0.96%	-3.74%	-9.65%	+8.42%	-1.90%
DARE Dare Bioscience	+1.51%	-4.17%	+1.36%	-62.24%	-63.90%
OPTH Optimi Health	+0.95%	-22.00%	-37.08%	-36.33%	+318,999,900.00%
SCNX Scienture	+0.90%	-12.44%	-59.22%	-67.34%	-81.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COCP Cocrystal Pharma	$1.02 -1.0%	$1.13	$0.76 ▼ $2.03	$19.84M	1.48	47,192 shs	22,775 shs
DARE Dare Bioscience	$0.72 -2.1%	$0.82	$0.69 ▼ $3.78	$14.56M	1.01	215,204 shs	77,209 shs
OPTH Optimi Health	$3.38 +6.0%	$4.59	$3.04 ▼ $6.40	$18.27M	N/A	35,560 shs	19,947 shs
SCNX Scienture	$3.36 -0.6%	$7.94	$3.21 ▼ $65.00	$5.55M	3.34	435,101 shs	24,146 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COCP Cocrystal Pharma	-0.96%	-3.74%	-9.65%	+8.42%	-1.90%
DARE Dare Bioscience	+1.51%	-4.17%	+1.36%	-62.24%	-63.90%
OPTH Optimi Health	+0.95%	-22.00%	-37.08%	-36.33%	+318,999,900.00%
SCNX Scienture	+0.90%	-12.44%	-59.22%	-67.34%	-81.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COCP Cocrystal Pharma	2.00	Hold	N/A	N/A
DARE Dare Bioscience	2.33	Hold	$6.50	797.05% Upside
OPTH Optimi Health	1.50	Reduce	N/A	N/A
SCNX Scienture	2.00	Hold	$37.50	1,016.07% Upside

Current Analyst Ratings Breakdown

Latest SCNX, COCP, OPTH, and DARE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	COCP Cocrystal Pharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/2/2026	SCNX Scienture	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
9/21/2026	SCNX Scienture	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/16/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/14/2026	DARE Dare Bioscience	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$1.00
8/27/2026	OPTH Optimi Health	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/25/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	COCP Cocrystal Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	DARE Dare Bioscience	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/17/2026	DARE Dare Bioscience	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/14/2026	OPTH Optimi Health	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	$0.46 per share	N/A
DARE Dare Bioscience	$1.03M	13.84	N/A	N/A	$0.20 per share	3.62
OPTH Optimi Health	$310K	62.48	N/A	N/A	N/A	∞
SCNX Scienture	$430K	12.81	N/A	N/A	$43.15 per share	0.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COCP Cocrystal Pharma	-$8.83M	-$0.76	N/A	N/A	N/A	N/A	-207.47%	-123.33%	11/13/2026 (Estimated)
DARE Dare Bioscience	-$13.40M	-$0.70	N/A	N/A	N/A	-803.80%	-748.30%	-38.75%	11/12/2026 (Estimated)
OPTH Optimi Health	-$1.12M	-$0.76	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SCNX Scienture	-$41.51M	-$52.50	N/A	N/A	N/A	N/A	-53.51%	-42.47%	11/11/2026 (Estimated)

Latest SCNX, COCP, OPTH, and DARE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	N/A	COCP Cocrystal Pharma	-$0.17	N/A	N/A	N/A	$0.11 million	N/A
11/12/2026	Q3 2026	DARE Dare Bioscience	-$0.14	N/A	N/A	N/A	$2.02 million	N/A
11/11/2026	Q3 2026	SCNX Scienture	-$1.50	N/A	N/A	N/A	$1.58 million	N/A
8/13/2026	Q2 2026	COCP Cocrystal Pharma	-$0.17	-$0.23	-$0.06	-$0.23	$0.11 million	$0.11 million
8/13/2026	Q2 2026	DARE Dare Bioscience	-$0.2967	-$0.20	+$0.0967	-$0.20	$0.00 million	$0.19 million
8/13/2026	Q2 2026	SCNX Scienture	-$2.25	-$0.07	+$2.18	-$1.75	$1.96 million	$0.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
OPTH Optimi Health	N/A	N/A	N/A	N/A	N/A
SCNX Scienture	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COCP Cocrystal Pharma	N/A	1.24	1.24
DARE Dare Bioscience	N/A	0.99	0.99
OPTH Optimi Health	0.04	0.06	0.03
SCNX Scienture	0.15	3.04	2.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COCP Cocrystal Pharma	6.72%
DARE Dare Bioscience	6.70%
OPTH Optimi Health	N/A
SCNX Scienture	5.68%

Insider Ownership

Company	Insider Ownership
COCP Cocrystal Pharma	39.40%
DARE Dare Bioscience	3.40%
OPTH Optimi Health	N/A
SCNX Scienture	19.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COCP Cocrystal Pharma	10	19.26 million	11.67 million	Not Optionable
DARE Dare Bioscience	24	19.67 million	19.00 million	Not Optionable
OPTH Optimi Health	9	5.73 million	N/A	N/A
SCNX Scienture	9	1.64 million	1.32 million	N/A

SCNX, COCP, OPTH, and DARE Headlines

Recent News About These Companies

SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth

October 13 at 8:05 AM | globenewswire.com

Contrasting Scienture (NASDAQ:SCNX) and Silo Pharma (NASDAQ:SILO)

October 7, 2026 | americanbankingnews.com

SCIENTURE Announces Arbli Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals

October 5, 2026 | marketscreener.comM

Exclusive: Scienture expands institutional reach for hypertension drug with new hospital adoptions

October 2, 2026 | msn.com

SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals

October 2, 2026 | globenewswire.com

Scienture announces 1-for-25 reverse stock split

September 30, 2026 | msn.com

Scienture Holdings, Inc. Announces Reverse Stock Split

September 30, 2026 | globenewswire.com

Scienture Expands REZENOPY Reach To Addiction Centers Under Distribution Deal

September 22, 2026 | rttnews.com

Scienture signs deal to sell Rezenopy at 2,000 addiction clinics

September 22, 2026 | streetinsider.com

SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner

September 22, 2026 | globenewswire.com

SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026

September 9, 2026 | globenewswire.com

Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses

August 14, 2026 | quiverquant.comQ

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

August 14, 2026 | globenewswire.com

Scienture Holdings Stock Price History

August 12, 2026 | investing.com

Scienture launches Rezenopy as second FDA-approved commercial product

August 12, 2026 | msn.com

SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray

August 12, 2026 | globenewswire.com

Scienture Holdings纳洛酮鼻喷雾剂7月将向美批发商发货

July 28, 2026 | finance.sina.com.cnF

Scienture Holdings stock jumps over 20% pre-market: Here's why

July 10, 2026 | msn.com

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

July 9, 2026 | finance.yahoo.com

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

July 9, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNX, COCP, OPTH, and DARE Company Descriptions

Cocrystal Pharma NASDAQ:COCP

$1.02 -0.01 (-0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$1.04 +0.02 (+1.96%)

As of 06:33 PM Eastern

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Dare Bioscience NASDAQ:DARE

$0.72 -0.02 (-2.08%)

Closing price 04:00 PM Eastern

Extended Trading

$0.73 +0.01 (+0.75%)

As of 07:55 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Optimi Health NASDAQ:OPTH

$3.38 +0.19 (+5.96%)

As of 04:00 PM Eastern

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. Optimi Health Corp. is based in VANCOUVER, BC.

Scienture NASDAQ:SCNX

$3.36 -0.02 (-0.59%)

Closing price 04:00 PM Eastern

Extended Trading

$3.28 -0.07 (-2.23%)

As of 07:56 PM Eastern

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SCNX, COCP, OPTH, and DARE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SCNX, COCP, OPTH, and DARE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SCNX, COCP, OPTH, and DARE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNX, COCP, OPTH, and DARE Company Descriptions

Cocrystal Pharma NASDAQ:COCP

Dare Bioscience NASDAQ:DARE

Optimi Health NASDAQ:OPTH

Scienture NASDAQ:SCNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SCNX, COCP, OPTH, and DARE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SCNX, COCP, OPTH, and DARE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SCNX, COCP, OPTH, and DARE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNX, COCP, OPTH, and DARE Company Descriptions

Cocrystal Pharma NASDAQ:COCP

Dare Bioscience NASDAQ:DARE

Optimi Health NASDAQ:OPTH

Scienture NASDAQ:SCNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools